Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2571 results about "Apoptosis" patented technology

Apoptosis (from Ancient Greek ἀπόπτωσις "falling off") is a form of programmed cell death that occurs in multicellular organisms. Biochemical events lead to characteristic cell changes (morphology) and death. These changes include blebbing, cell shrinkage, nuclear fragmentation, chromatin condensation, chromosomal DNA fragmentation, and global mRNA decay. The average adult human loses between 50 and 70 billion cells each day due to apoptosis. For an average human child between the ages of 8 to 14 years old approximately 20 to 30 billion cells die per day.

Application of RNF130 activator in preparation of medicine for preventing and / or treating ischemic heart disease

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating ischemic heart disease, and belongs to the technical field of biological medicine. Research results show that when an RNF130 activator is given in a mouse of a myocardial ischemia reperfusion injury model, the left ventricular ejection fraction and the left ventricular short-axis shortening rate of the mouse can be improved, myocardial tissue pathological injury can be relieved, the protein expression levels of NOX-2, BAX and TNF-alpha are reduced, the myocardial infarction area is reduced, and myocardial cell apoptosis is reduced; therefore, the RNF130 activator has prevention and treatment effects on the myocardial ischemia-reperfusion injury, that is, the RNF130 activator can be used as an effective component of the medicine for preventing or treating diabetes complicated by myocardial ischemia-reperfusion injury, and a new strategy is provided for preparation of the medicine for preventing and treating myocardial ischemia-reperfusion injury.
Owner:JIANGNAN UNIV

Medical simulation experiment method and device for acting apoptosis vesicles on primary cartilage cells based on cell line culture

The invention relates to a medical simulation experiment method and device for acting apoptosis vesicles on primary cartilage cells based on cell line culture, and the method mainly comprises the following steps: S1, co-culture system construction, S2, multi-dimensional observation and analysis, and S3, operation risk assessment. In the step S1, primary cartilage cells, primary immune cells and cell line culture apoptosis vesicles are co-cultured; s2, carrying out multi-dimensional observation and analysis on the influence of apoptosis vesicles on cells; and S3, mainly constructing a multi-dimensional risk scoring system, and carrying out risk grade division by applying a biological network model. The invention aims at simulating and evaluating the influence of cell line culture apoptosis vesicles on primary cartilage cells in vitro and the interaction between the cell line culture apoptosis vesicles and primary immune cells, so that an experimental basis is provided for subsequent clinical application.
Owner:HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)

Effect of Collagen in relieving damage of vomitoxin to bovine rumen epithelial cells by vitamin E

The invention discloses an effect of Collagen in relieving vomitoxin injury of bovine rumen epithelial cells by vitamin E, and belongs to the technical field of genetic engineering, the Collagen is COL1A1 protein, COL2A1 protein and COL5A1 protein; the amino acid sequence of the COL1A1 protein is as shown in SEQ ID NO. 19; the amino acid sequence of the COL2A1 protein is as shown in SEQ ID NO. 20; the amino acid sequence of the COL5A1 protein is as shown in SEQ ID NO. 21. According to the effect of Collagen in relieving bovine rumen epithelial cells damaged by vomitoxin through vitamin E, it is found that vitamin E can effectively protect the cell membrane integrity of the bovine rumen epithelial cells and can relieve cell viability decline, oxidative stress, immune and inflammatory reactions and the cell apoptosis rate caused by DON; vitamin E can promote ECM receptor effect and protein digestion and absorption ways by adjusting Collagen protein so as to protect rumen epithelial cells of dairy cows.
Owner:JILIN AGRICULTURAL UNIV

Application of isorhamnetin-3-O-neohesperidin in preparation of medicine for preventing and / or treating benign prostatic hyperplasia

The invention discloses an application of isorhamnetin-3-O-neohesperidin in preparation of a medicine for preventing and / or treating benign prostatic hyperplasia. In-vitro experiments show that the isorhamnetin-3-O-neohesperidin can inhibit proliferation of prostatic hyperplasia cells, promote apoptosis of the prostatic hyperplasia cells and regulate inflammatory response of the prostatic hyperplasia cells, and rat experiments show that the isorhamnetin-3-O-neohesperidin can improve the hormone endocrine disorder condition of an animal model body, and can inhibit the prostatic hyperplasia cells and promote the prostatic hyperplasia cell apoptosis and regulate the inflammatory response of the prostatic hyperplasia cells. The anti-inflammatory ability of an animal model is enhanced, and the traditional Chinese medicine composition has a relatively good treatment effect on prostatic hyperplasia caused by testosterone propionate. The medicine for preventing and / or treating benign prostatic hyperplasia, provided by the invention, contains a pharmacodynamic dose of isorhamnetin-3-O-neohesperidin and a pharmaceutically acceptable carrier or auxiliary material, can be prepared into a medicine dosage form which is convenient for clinical use and can play an optimal curative effect, and has a relatively high clinical application value.
Owner:CHINA PHARM UNIV

Scylla paramamosain live-keeping and soft-shell soft-keeping method

The invention discloses a scylla paramamosain keep-alive and soft shell soft-keeping method, a low-temperature keep-alive mode refers to an on-ice keep-alive mode or a low-temperature acidification keep-alive mode, preferably, the low-temperature acidification keep-alive mode: cooling seawater to 16 DEG C or below by using a cooling-water machine, then adjusting the pH value of the seawater to be less than 8 to obtain low-temperature acidified seawater, and then cooling the low-temperature acidified seawater to obtain the scylla paramamosain soft shell soft-keeping method. And putting the soft-shell crabs which just molt into low-temperature acidified seawater for keeping alive and softness. The hardening of the soft shell can be obviously delayed by low-temperature acidified seawater and on-ice keep-alive; low-temperature acidified seawater and on-ice keep-alive soft-shell crabs can improve the delicate flavor and sweet taste of hepatopancreas of the soft-shell crabs, and the flavors of the two keep-alive soft-shell crabs are better than those of cold-stored dead soft-shell crabs; on-ice and low-temperature acidified seawater keep-alive interferes with glycolipid metabolism, oxidative stress and cell apoptosis of the soft-shell crabs, and compared with on-ice keep-alive, low-temperature acidified seawater keep-alive influences are milder than on-ice keep-alive.
Owner:NINGBO UNIV

Application of sea cucumber-derived nano-vesicles in preparation of medicine for promoting wound repair

The invention relates to application of sea cucumber-derived nano-vesicles in preparation of a medicine for promoting wound repair. The nano-vesicles (SC-EVs) extracted and prepared from sea cucumbers can effectively promote cell migration, scratch repair and tube forming capabilities of human skin epithelial cells (HACAT) and human skin microvascular endothelial cells (HM DEC) and inhibit cell apoptosis, so that the capability of repairing cells is achieved, and particularly the effect of repairing wound surfaces in a high glucose state or diabetes mellitus is achieved. The invention provides a new direction and thought for the application of the sea cucumber-sourced nano vesicles (SC-EVs), provides a brand new drug research and development and clinical treatment direction for wound repair, especially for solving the problem of difficult healing of wounds of patients with high glucose or diabetes, and has extremely high social value and market application prospect.
Owner:JINAN UNIVERSITY

HER2 positive breast cancer targeting functional drug-loading small molecule peptide

The invention discloses a functional drug-loading small molecule peptide targeting HER2 positive breast cancer, and belongs to the technical field of establishment and preparation of a small molecule peptide nano-drug carrier system. The peptide contains HER2 targeting peptide, responds to alkaline phosphatase in a tumor microenvironment, can be used as a drug carrier, and has a structural formula as shown in Figure 1. The functional drug-loading small molecule peptide can improve the cytotoxicity to tumor cells and reduce the toxic and side effects to normal cells. The DC / Pep1 is subjected to morphology transformation under the induction of ALP in a tumor microenvironment, and the DC / Pep1 carries DOX and CUR together, so that the residence time of the combined drug in HER2 positive tumor cells is prolonged, and tumor cell migration is more effectively inhibited and cell apoptosis is more effectively promoted.
Owner:WEIFANG MEDICAL UNIV

Methods for treating cancers and tumors

Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. Some embodiments relate to methods of inhibiting proliferation of a cancer cell. Some embodiments relate to a method of inducing apoptosis in a cancer cell. In some embodiments, the methods include administering a compound of Formula (I) to a subject in need thereof.
Owner:BEYONDSPRING PHARMACEUTICALS INC

Seaweed-derived extract, organism-applied product using the same, and method for extracting seaweed-derived exosome

To scientifically prove a pharmacological effect and to promote effective use for a fucoidan reported effective for increasing an immune strength and anticancer activity.SOLUTION: A raw material, Mozuku, is hydrolyzed (boiled) to provide a low molecular fucoidan. Then, a nano-level particle group is extracted from the low molecular fucoidan through super-centrifugal separation or the like using a supercentrifuge 1. The major part of the particle group is within the size of 50-200 nm, and composed of exosome carrying miRNA or meRNA. Exosome derived from the fucoidan acts both for apoptosis-induction for an abnormal organ suffering from ulcer or cancer and reproduction for promoting growth of a normal organ, and safe and resistant / non-dependent. Thus, the exosome derived from the fucoidan can be adopted for various products such as a medicine.SELECTED DRAWING: Figure 2
Owner:落谷 孝広 +1

Application of MDH2 inhibitor in preparation of preparation for reducing toxicity of fumonisins

The invention discloses application of an MDH2 inhibitor in preparation of a preparation for reducing toxicity of fumonisins, and belongs to the technical field of biology. A fumonisins treatment experiment is carried out on MDH2 gene mutant cells and wild type MDH2 gene cells, and the result shows that the cell activity of the MDH2 gene mutant cells is remarkably improved by 15.2% compared with that of wild type MDH2 gene expression cells under the condition that the fumonisins concentration is 100 micrograms / mL, the cell apoptosis rate is remarkably reduced by 7.76%, and the cell apoptosis rate can be reduced by 7.76%. Therefore, the MDH2 gene mutation can improve the tolerance to the fumonisins. In addition, the LW6 inhibitor is used for inhibiting the MDH2 activity of the wild type IPEC-J2 cell, and the tolerance of the cell to the fumonisins can also be improved. The invention provides a potential solution way for preventing adverse reaction caused by fumonisins, and provides a theoretical basis for preventing and controlling harm of FB1 to food and animal husbandry.
Owner:AGRO BIOLOGICAL GENE RES CENT GUANGDONG ACADEMY OF AGRI SCI

Application of NR4A1 gene expression inhibitor in preparation of medicine for treating wine-dependent withdrawal

PendingCN119524128AReduce prefrontal apoptosis proteinReduce apoptotic proteinOrganic active ingredientsNervous disorderPrefrontal lobeApoptosis
The invention belongs to the technical field of biological medicines, and particularly relates to application of an expression inhibitor of an NR4A1 gene in preparation of a medicine for treating wine-dependent withdrawal. It is found that after wine-dependent withdrawal, mice have anxiety behaviors, the NR4A1 level of the prefrontal lobe is increased, and apoptosis-related protein in the prefrontal lobe is increased. Knockout of the forehead NR4A1 gene intervenes the expression level of the NR4A1 gene in the forehead lobe of the mouse, it can be proved that down-regulation of the expression of the forehead lobe NR4A1 gene can rescue apoptosis and damage, caused by alcohol, of cortical neurons of the forehead lobe, relieve anxiety behaviors caused by alcohol withdrawal of the mouse, and have the effect of protecting the brain of the mouse; the inhibitor DIM-C-pPhOH of the NR4A1 protein can reduce the expression of the NR4A1 gene of the prefrontal lobe of an alcohol withdrawal mouse and anxiety-like behaviors caused by alcohol withdrawal, and provides related therapeutic targets and new therapeutic drugs for anxiety dysfunction caused by clinical alcohol dependence and alcohol dependence withdrawal.
Owner:河南医药大学第二附属医院(河南省精神病医院)

Medical application of DNAJB6 in prevention or treatment of myocardial infarction

The invention belongs to the field of biological medicines, and particularly discloses application of DNAJB6 in preparation of medicines for preventing or treating myocardial infarction (MI). In-vivo and in-vitro experiments find that the expression of DNAJB6 protein in an MI model is remarkably reduced, and the over-expression of DNAJB6 can improve the cardiac function of a mouse after MI, relieve myocardial fibrosis and inhibit hypoxia-induced myocardial apoptosis; and cell apoptosis is aggravated by low expression of DNAJB6. The overexpression of the DNAJB6 by using the myocardial specific adeno-associated virus (AAV) can be used as a new strategy for preventing and treating the MI, and an experimental basis is provided for developing a drug for targeting the DNAJB6.
Owner:GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY

Eye drops containing recombinant protein as well as preparation method and application of eye drops

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.
Owner:TIANJIN UNIVERSITY OF TECHNOLOGY

Application of Ackermania muciniphila or extracellular vesicles thereof in preparation of medicine for alleviating alcoholic ischemic necrosis of femoral head

The invention belongs to the field of biological medicines, and discloses an application of Akkermansia muciniphila or an extracellular vesicle of the Akkermansia muciniphila in preparation of a medicine for alleviating the ischemic necrosis of the alcoholic femoral head. Based on the pathogenesis characteristics of the AIONFH, the Akk bacteria and the extracellular vesicles thereof are used for treating the AIONFH for the first time, the molecular mechanism of the Akk bacteria and the extracellular vesicles thereof for regulating and controlling the intestinal tract-skeleton axis function, inhibiting bone cell apoptosis and improving the bone trabecula microstructure is deeply researched, the anti-pressure ability of bone tissue is improved, and the research blank in the field is filled. Compared with a traditional treatment method, the osteonecrosis pathological change is improved through a single way, and a novel multi-target treatment strategy is provided from multiple aspects of regulating inflammatory response, recovering bone metabolism balance, promoting intraosseous blood supply and the like.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV

Application of Wnt2 gene in buffalo ovarian granular cells

PendingCN119592628Apromote proliferationHigh expressionGenetically modified cellsNucleic acid vectorSignaling Pathway GeneGranular cell
The invention discloses application of a Wnt2 gene in buffalo ovarian granular cells, and belongs to the technical field of cell engineering and gene engineering. Wnt2 is taken as a research object, the Wnt2 overexpression vector or Wnt2 siRNA is transfected to the ovarian granulosa cells respectively by constructing the Wnt2 overexpression vector and synthesizing small interfering RNA (Wnt2 siRNA), then changes of signal channel gene mRNA and protein level related to ovarian granulosa cell apoptosis, proliferation and E2 and P4 secretion are detected, and finally phenotypic changes of the ovarian granulosa cells are detected. Results show that Wnt2 can inhibit apoptosis of ovarian granular cells and promote proliferation and E2 and P4 secretion. By exploring the application of the Wnt2 in the ovarian granular cells, the application has good application in researching an ovarian follicle atresia mechanism, initial estrus initiation and the like.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION BUFFALO INST

Postbiotic hydrogel for relieving alcoholic gastric ulcer as well as preparation method and application thereof

The invention belongs to the technical field of biological medicines, and particularly relates to a postbiotic hydrogel for relieving alcoholic gastric ulcer as well as a preparation method and application thereof. The metagen hydrogel for relieving the alcoholic gastric ulcer, provided by the invention, is mainly prepared from metagen of rhamnobacter and modified lactoferrin; the lactobacillus rhamnosus is lactobacillus rhamnosus JM023. Tests prove that when the postbiotic hydrogel is applied to an alcoholic gastric ulcer rat model, the occurrence of gastric ulcer can be inhibited by inhibiting oxidative stress and inflammatory response and improving protection factor secretion; and the alcoholic gastric ulcer is relieved by regulating and controlling the expression of oxidation, inflammation, cell apoptosis and tissue repair related metabolic pathways and regulating gastrointestinal flora. The metagen hydrogel disclosed by the invention has the effect of effectively relieving gastric ulcer symptoms caused by alcohol, and is suitable for being developed and applied as a medicine or a health-care product for relieving alcoholic gastric ulcer.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Copper complex with anticancer activity and preparation method and application thereof

The invention belongs to the field of anti-cancer metal complexes, and particularly relates to a copper complex with anti-cancer activity and a preparation method and application thereof. Cu (OAc) 2H2O and coumarin-3-formyl-(2-aminomethylpyridine) are respectively dissolved in a solvent, the two solutions are mixed and stirred at room temperature to react for a period of time, the reaction solution is filtered, the filtrate is sealed and naturally volatilized at room temperature for 3-7 days, the complex can be obtained, the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M, and the IC50 value of the complex to Hela cervical cancer cells is 0.8964 + / -0.09 mu M. According to the present invention, the inhibition effect of the complex on HeLa cervical cancer cells is 3.38 times of the inhibition effect of cis-platinum, the toxicity of the complex on normal cells but HUVEC is very small, IC50 is greater than 100 [mu] M, and the complex has a high selectivity coefficient SI (SI = normal cell IC50 / cancer cell IC50), and the selectivity coefficient SI is greater than 111 and is 584 times of the selectivity coefficient of cis-platinum (SI = 0.19). The complex has the capability of inducing apoptosis of cancer cells and has concentration dependence. Meanwhile, the complex can retard cancer cells and an S phase so as to inhibit cell proliferation, and can generate an intercalation effect with HS-DNA (High-Speed Deoxyribose Nucleic Acid).
Owner:NANJING FORESTRY UNIV

Application of daphnetin in preparation of medicine for treating renal clear cell carcinoma

The invention relates to application of daphnetin in preparation of a medicine for treating renal clear cell carcinoma, and belongs to the technical field of medicines. The invention aims to provide a novel application of daphnetin in treatment of renal clear cell carcinoma, and particularly relates to an application of daphnetin in preparation of a medicine for treating renal clear cell carcinoma. According to the application, the advantages of multiple components, multiple targets and small adverse reaction of traditional Chinese medicine are fully utilized, the daphnetin is used for acting on renal clear cell carcinoma cell lines 786-O and 769-P, and experiments verify that the daphnetin has the effects of inhibiting proliferation, migration and invasion of 786-O and 769-P cells and promoting apoptosis of the two cells; therefore, the invention provides the new application of the daphnetin in treating the renal clear cell carcinoma, particularly the application of the daphnetin in preparing the medicine for treating the renal clear cell carcinoma, and an experimental basis and a new strategy are provided for clinical treatment of the renal clear cell carcinoma.
Owner:HEILONGJIANG UNIV OF CHINESE MEDICINE

Application of iNOS inhibitor in preparation of medicine for relieving cell injury caused by toxin combined exposure

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.
Owner:ZHENGZHOU UNIV

Nucleic acid aptamer-based covalent lysosome targeting chimera and application thereof in protein degradation and immunotherapy

The invention discloses a covalent lysosome targeting chimera based on a nucleic acid aptamer and application of the covalent lysosome targeting chimera in protein degradation and immunotherapy, and belongs to the technical field of biology. The invention designs a covalent lysosome targeting chimera with click chemical reaction activity, and the simple and efficient covalent lysosome targeting chimera is used for realizing efficient protein degradation at the levels of cells and living bodies. When the tool is used for targeted degradation of immunotherapy biomarkers, immunogenic apoptosis of tumor cells can be caused, so that killing of an immune system to tumors is more efficiently activated. Meanwhile, the covalent lysosome targeting chimera overcomes the problem of immune-related side effects confronted by existing antibodies and polysaccharide peptide drugs, and can effectively avoid the potential occurrence risk of the immune-related side effects while efficiently degrading the target protein.
Owner:刘庄

Cream casein hydrolysate as well as preparation method and application thereof

The invention provides a cheese protein hydrolysate as well as a preparation method and application thereof. The composition of the casein hydrolysate at least comprises at least one of a peptide fragment 1 with an amino acid sequence as shown in SEQ ID NO: 1, a peptide fragment 2 with an amino acid sequence as shown in SEQ ID NO: 2 and a peptide fragment 3 with an amino acid sequence as shown in SEQ ID NO: 3. The casein hydrolysate has good neuron protection and repair effects, and can improve cholinergic neuron and dopaminergic neuron damage; abeta protein deposition can be inhibited, so that neuronal synaptic disorder, neuronal apoptosis and brain injury caused by Abeta protein deposition are relieved; the cholinergic defect can be improved, so that the nerve development damage and the behavior and movement disorder caused by the cholinergic defect are relieved; and damaged neurons in hippocampus and hypothalamus can be repaired, so that the brain environment is kept stable.
Owner:AUSNUTRIA DAIRY CHINA

Lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as product and application of lactobacillus rhamnosus

The invention discloses lactobacillus rhamnosus for improving thrombus and cerebral apoplexy as well as a product and application thereof, and relates to the technical field of microorganisms. The lactobacillus rhamnosus NHNK-604 disclosed by the invention is preserved in the China Center for Type Culture Collection on March 7, 2024, and the preservation number of the lactobacillus rhamnosus NHNK-604 is CCTCC (China Center for Type Culture Collection) NO: M 2024417. The NHNK-604 has the functions of dissolving thrombus, regulating blood coagulation factors of vascular endothelial cells, reducing inflammation and apoptosis of the vascular endothelial cells, reducing aging damage of cerebral micro-blood endothelial cells and promoting blood-brain barriers. In addition, the thallus biological membrane can increase colonization of mucoprotein and intestinal epithelial cells, and can be used for preparing products for improving thrombus and cerebral apoplexy.
Owner:QINGDAO NOVO NUOKANG BIOTECHNOLOGY CO LTD

Application of collagen-gelatin combined VEGF (vascular endothelial growth factor) mimetic peptide in promoting growth of blood vessels

The invention relates to the technical field of medical instruments, and discloses an application of a collagen-gelatin combined VEGF (vascular endothelial growth factor) mimic peptide in promoting growth of blood vessels, the collagen-gelatin combined VEGF mimic peptide is QKCMP-Enhancer, and the sequence of the collagen-gelatin combined VEGF mimic peptide is Ac-KLTWQELYQLKYKGI-(GPO) 5-(KR) 4-(RGD) 4-(KR) 4-GGG-(Gly) 3-NH2. The invention discloses a collagen-gelatin combined VEGF (vascular endothelial growth factor) mimic peptide which shows remarkable biological activity in the aspects of promoting angiogenesis, stimulating cell proliferation and inhibiting cell apoptosis. A new way and a new strategy are developed for treating related diseases; the collagen-gelatin is combined with the VEGF mimic peptide, so that a safer, more efficient and controllable angiogenesis method can be realized, and the collagen-gelatin combined VEGF mimic peptide has remarkable clinical application potential.
Owner:NINGBO FIRST HOSPITAL +2

Tissue engineering full-thickness skin model and construction method

The invention provides a tissue engineering full-thickness skin model and a construction method, the full-thickness skin model is constructed on the basis of dermal fibroblasts and epidermal cells, and an extracellular matrix and components required for maintaining cell growth are added to promote the formation of a dermal layer and an epidermal layer. Meanwhile, the added matrigel contains a basement membrane component, anchoring, proliferation and differentiation of keratinocytes are facilitated, meanwhile, the contained basement membrane component provides a template for rapid development of the basement membrane of the full-thickness skin model, deposition of the basement membrane component by human epidermal cells and fibroblasts is promoted, and the apoptosis of the human epidermal cells and the fibroblasts is promoted. The interaction among the components of the basement membrane is accelerated, so that the rapid formation of the basement membrane with a complete ultrastructure is facilitated, and the tight connection of the true epidermis of the model is promoted. The fibronectin can promote the adhesion growth of cells to maintain the body structure and cell growth, so that the connection between the corium layer and the epidermal layer is tighter. The full-thickness skin model comprises an epidermal layer, a basement membrane and a corium layer which are tightly connected, is similar to a normal skin structure and can be used for safety or efficacy detection of products such as drugs, chemicals, cosmetics and disposable medical instruments.
Owner:济南磐升生物技术有限公司

Application of NR1D1 gene in regulation and control of granular cells

PendingCN119530136Aregulatory activityOptimize the in vitro culture systemCell receptors/surface-antigens/surface-determinantsFermentationGranular leucocyteApoptosis
The invention relates to application of an NR1D1 gene in regulation and control of granular cells, and belongs to the technical field of biology. The invention provides an application of an NR1D1 gene in regulation and control of granulosa cells, including an application of a sequence shown in siRNA of the NR1D1 gene in preparation of a product for regulation and control of sheep granulosa cells, and the sequence is shown in SEQ ID NO: 1 and SEQ ID NO: 2. According to the regulation method and product of the granulosa cells, the proliferation apoptosis and activity of the granulosa cells can be effectively regulated, and the expression of follicular development related genes can be regulated. The method has the beneficial effects that in-vivo or in-vitro regulation and control effects on follicles and / or ovaries are realized, and a method and a product guarantee are provided for research on development and physiological and biochemical functions of granular cells, follicles and ovaries.
Owner:NANJING AGRICULTURAL UNIVERSITY

Application of stem cell composition in endometrial repair

The invention provides a stem cell composition for treating endometrial repair. Specifically, the invention also provides an oligopeptide ZGC-5 which can significantly inhibit ectopic endometrial cell proliferation and has therapeutic activity, and the oligopeptide has the effects of inhibiting ectopic endometrial cell proliferation and promoting apoptosis. After the oligopeptide and the stem cells are prepared into the medicine box, the medicine box has a good effect of treating endometriosis.
Owner:XIAN JINGCAI BIOTECHNOLOGY CO LTD

Preparation of polypeptide hydrogel and application of polypeptide hydrogel in myocardial ischemia-reperfusion injury

The invention discloses preparation of polypeptide hydrogel and application of the polypeptide hydrogel in myocardial ischemia reperfusion injury. Belongs to the technical field of biotechnology and new medicine, the hydrogel polypeptide gel forming factor YFF-TK-FFY (the structural sequence is tyrosine-phenylalanine-phenylalanine-thioketal-phenylalanine-phenylalanine-tyrosine) and the fat cell factor Apelin-13 are assembled, and the ROS responsive polypeptide hydrogel YFF-TK-FFY / Apelin-13 (Apelin-13 at Gel TK) is formed. The polypeptide hydrogel Apelin-13 (at) Gel TK has the advantages that the biocompatibility and the biodegradability are good; thioketal bonds in the gelling factors can respond to high-level ROS in a myocardial ischemia reperfusion injury core area and then break, namely YFF-TK-FFY generates YFF-SH, so that hydrogel disintegrates and Apelin-13 is quickly released, and myocardial cell apoptosis is effectively relieved; the ROS level in the marginal area is relatively low, and the hydrogel is slow in peptization, so that the Apelin-13 is continuously and slowly released to promote angiogenesis; the research shows that the polypeptide hydrogel Apelin-13-coated Gel TK has a remarkable treatment effect in the aspect of relieving the myocardial ischemia reperfusion injury.
Owner:SOUTHEAST UNIV

Establishment method of umbilical cord mesenchymal stem cells highly expressing IGF-1 and application of umbilical cord mesenchymal stem cells in premature ovarian failure

The invention provides an establishment method of umbilical cord mesenchymal stem cells with high expression of IGF-1 (Insulin-like Growth Factor 1) and application of the umbilical cord mesenchymal stem cells in premature ovarian failure. The construction method of the umbilical cord mesenchymal stem cells with high expression of IGF-1 comprises the step of transfecting the umbilical cord mesenchymal stem cells with the IGF-1 gene, so that the umbilical cord mesenchymal stem cells highly express IGF-1. The invention also provides application of the umbilical cord mesenchymal stem cell with high expression of IGF-1 in preparation of drugs for treating premature ovarian failure. According to the invention, the IGF-1 gene is transfected to the hUC-MSC, so that the hUC-MSC highly expresses the IGF-1, and the hUC-MSC secretes a large amount of IGF-1. The ovarian function is improved through the immunoregulation effect of hUC-MS, and meanwhile, the effect of resisting apoptosis of granular cells is achieved through IGF-1 secreted by hUC-MS. And the treatment effect on the premature ovarian failure is achieved through synergism of the two effects.
Owner:JIANGSU TOPCEL-KH PHARMACEUTICAL CO LTD

Application of oleanolic acid as feed additive in improving laying rate of laying hens

PendingCN118901909AImprove egg production performanceimprove qualityOrganic active ingredientsAntipyreticBiotechnologyAnimal science
The invention discloses an application of oleanolic acid as a feed additive in improving the laying rate of laying hens. The oleanolic acid achieves the purpose of relieving ovarian inflammatory response of laying hens by inhibiting mRNA expression of proinflammatory factors IL-8 and P21. The oleanolic acid achieves the purpose of relieving ovarian cell apoptosis by inhibiting mRNA expression of BAX, BCL-2 and Caspase-3 in an apoptosis signal channel. The feed additive disclosed by the invention is a plant extract, is natural, safe and environment-friendly in source, and after the aged laying hens are fed with the feed additive disclosed by the invention, the egg laying capacity of the aged laying hens is obviously improved, the egg quality is improved to a certain extent, and the ovarian aging of the laying hens is also slowed down.
Owner:ZHEJIANG UNIV

Plant external vesicle combined preparation for treating non-small cell lung cancer as well as preparation method and application of plant external vesicle combined preparation

The invention relates to the technical field of biological medicine, and particularly discloses a plant exovesicle combined preparation for treating non-small cell lung cancer and a preparation method and application thereof, and the plant exovesicle combined preparation comprises ginseng exovesicles and turmeric exovesicles. The plant external vesicle combined preparation provided by the invention is used for inhibiting non-small cell lung cancer cells and promoting apoptosis of the non-small cell lung cancer cells, and can be used for preparing medicines for treating the non-small cell lung cancer.
Owner:CHANGSHA SHIHAO BIOTECHNOLOGY CO LTD